{"id":2315,"date":"2026-06-11T20:00:00","date_gmt":"2026-06-11T23:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2315"},"modified":"2026-06-11T20:00:00","modified_gmt":"2026-06-11T23:00:00","slug":"pgrss-clinica-medicina-cir-oncologica-testicular-avancada-rplnd-pc-rplnd-bep-veip-tip-hdct-auto-tmo-precog","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/pgrss-clinica-medicina-cir-oncologica-testicular-avancada-rplnd-pc-rplnd-bep-veip-tip-hdct-auto-tmo-precog\/","title":{"rendered":"PGRSS testic avan: RPLND, BEP, HDCT, PRECOG"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores de cl\u00ednicas de cirurgia oncol\u00f3gica testicular avan\u00e7ada que reduzem PGRSS a descarte de bisturi e gaze<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 cl\u00ednicas de cir oncol\u00f3gica testicular avan\u00e7ada<\/strong> + TGCT tumor c\u00e9lulas germinativas seminoma puro+n\u00e3o-seminoma EC+YST+TER+CHC misto+CIS ITGCN GCNIS<\/strong> + IGCCCG good+intermediate+poor risk PRECOG+EORTC GETUG<\/strong> + orquiectomia radical inguinal alta+RPLND retroperitoneal nerve-sparing+template Donohue+rob\u00f3tica Da Vinci Xi+SP+Medtronic Hugo+RAMIE Robot-Assisted RPLND<\/strong> + PC-RPLND post-chemotherapy retroperitoneal residual mass\u22651cm+desmoplastic stroma+teratoma maduro+yolk sac residual<\/strong> + BEP bleomicina+etoposide+cisplatina 3-4 ciclos+EP etoposide+cisplatina+VeIP vinblastina+ifosfamida+cisplatina+TIP paclitaxel+ifosfamida+cisplatina salvage 2L+HDCT high-dose chemotherapy+auto-TMO aut\u00f3logo+CBC carboplatina+etoposide alta dose<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (TGCT seminoma+EC+YST+TER+CHC+CIS ITGCN GCNIS) + Grupo A4 (RPLND retroperitoneal nerve-sparing+modified template Donohue+full bilateral+PC-RPLND post-chemo+linfa para-a\u00f3rtica+interaortocaval+paracaval+supra-hilar) + Grupo C (Iridium-192 brachy testicular raro+I-131 met\u00e1stase raro+Y-90 SIRT raro) + Grupo E (perfuro bi\u00f3psia testicular contralateral CIS screening+Vacutainer marcadores AFP+\u03b2-hCG+LDH+seriado) + Lista C5 (BEP bleomicina Blenoxane+etoposide Vepesid+cisplatina Platinol IGCCCG good 3 BEP+intermediate 4 BEP+poor 4 BEP+EP 4 cycles+VeIP+TIP salvage 2L PFS 24m HR favor\u00e1vel+HDCT high-dose chemo+auto-TMO aut\u00f3logo CBC carbo AUC 12-15+etoposide 1500 mg\/m\u00b2+TI-CE Mayo Clinic+TIGER trial+gemcitabina+oxaliplatina GemOx+pembrolizumab Keytruda raro+nivolumab raro+olaratumab descontinuado Lista C5).<\/p>\n

Para o gestor que opera ou planeja cl\u00ednica de cir oncol\u00f3gica testicular avan\u00e7ada, \u00e9 fundamental dimensionar PGRSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos oncol\u00f3gicos testiculares avan\u00e7ados<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o PGRSS testicular avan\u00e7ada tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
A1 TGCT seminoma+n\u00e3o-sem<\/td>\n4-12 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nEC+YST+TER+CHC+CIS<\/td>\n<\/tr>\n
A4 RPLND+PC-RPLND+robot<\/td>\n4-11 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nDonohue+nerve-sparing<\/td>\n<\/tr>\n
C Iridium-192+I-131<\/td>\n0,4-1,2 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nRaro+CNEN<\/td>\n<\/tr>\n
E bi\u00f3psia CIS+marcador<\/td>\n0,5-1,5 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nAFP+\u03b2-hCG+LDH seriado<\/td>\n<\/tr>\n
BEP+VeIP+TIP+HDCT<\/td>\n1,5-4,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nIGCCCG+TIGER+TI-CE<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 10,4-30,2 kg\/dia<\/strong> em cl\u00ednica cir oncol\u00f3gica testicular avan\u00e7ada m\u00e9dia porte.<\/p>\n

A1 TGCT + IGCCCG + PRECOG + GETUG: o est\u00e1gio cir\u00fargico+estadiamento<\/h2>\n

A primeira camada do PGRSS testicular avan\u00e7ada \u00e9 A1. Padr\u00e3o setorial inclui (a) TGCT tumor c\u00e9lulas germinativas<\/strong> com seminoma puro 50% radiossens\u00edvel + n\u00e3o-seminoma 50% misto + EC carcinoma embrion\u00e1rio + YST yolk sac tumor + TER teratoma maduro+imaturo + CHC coriocarcinoma + CIS ITGCN GCNIS germ cell neoplasia in situ contralateral risk; (b) marcador tumoral<\/strong> com AFP alfa-fetoprote\u00edna (n\u00e3o-seminoma YST+EC+TER) + \u03b2-hCG beta-gonadotrofina (CHC+EC) + LDH lactato desidrogenase + seriado q3w monitoramento + CR criterion sustained normal markers; (c) IGCCCG International Germ Cell Cancer Collaborative Group<\/strong> com seminoma good+intermediate poor + n\u00e3o-seminoma good+intermediate+poor risk + sobrevida 5y good 90+%\/intermediate 80%\/poor 50-60%; (d) PRECOG Pediatric Outcomes Cooperative+EORTC GETUG French<\/strong> com SCT trial + IT-94 + TE08+TE13 RCT randomizados padr\u00e3o protocolos europeus + Northern UK BEP standard; (e) estadiamento TNM 8\u00aa edi\u00e7\u00e3o+UICC<\/strong> Tis ITGCN+T1a\/T1b lymphovascular+T2 invade rete testis+T3 cord\u00e3o+T4 escrotal+N1-N3+M1a\/M1b dist\u00e2ncia+S0-S3 marcadores+CID C62.<\/p>\n

Cl\u00ednica com A1 TGCT madura garante estadiamento IGCCCG good\/intermediate\/poor<\/strong> + previne semeadura escrotal<\/strong> + otimiza marcador AFP+\u03b2-hCG+LDH seriado<\/strong>. Como discutimos no post sobre testicular<\/a>, A1 testicular \u00e9 base.<\/p>\n

A4 orquiectomia + RPLND + PC-RPLND + nerve-sparing + rob\u00f3tica RAMIE: o est\u00e1gio cir\u00fargico<\/h2>\n

A segunda camada \u00e9 t\u00e9cnica. Padr\u00e3o setorial inclui (a) orquiectomia radical inguinal alta<\/strong> com cord\u00e3o esperm\u00e1tico ligado anel inguinal interno + via inguinal alta N\u00c3O escrotal semeadura + Chevassu maneuver clamp + bi\u00f3psia testicular contralateral CIS screening 5%; (b) RPLND Retroperitoneal Lymph Node Dissection<\/strong> com modified template Donohue + full bilateral + nerve-sparing t\u00e9cnica preservar plexo simp\u00e1tico lombar L1-L4 + ejacula\u00e7\u00e3o anter\u00f3grada 80-95% nerve-sparing vs 5-20% template completo; (c) PC-RPLND post-chemotherapy<\/strong> com residual mass \u22651cm p\u00f3s-BEP\/EP + necrose 40% + teratoma maduro 40% + yolk sac\/EC residual 20% + indica\u00e7\u00e3o seminoma desmoplastic stroma + standard non-seminoma; (d) abordagem cir\u00fargica<\/strong> com aberto incis\u00e3o thoracoabdominal\/laparotomia + laparoscopia + rob\u00f3tica Da Vinci Xi + RARLPND robotic-assisted + RAMIE Robot-Assisted Minimally Invasive RPLND; (e) complica\u00e7\u00e3o<\/strong> chyloperitoneum 5-15% + ileus 10-25% + ejacula\u00e7\u00e3o retr\u00f3grada nerve-sparing vs template + linfocele + les\u00e3o vascular grandes vasos + DVT\/TEP.<\/p>\n

Cl\u00ednica com A4 RPLND+PC-RPLND+nerve-sparing+rob\u00f3tica madura escala R0 90+% PC-RPLND<\/strong> + escala nerve-sparing ejacula\u00e7\u00e3o 80-95%<\/strong> + escala rob\u00f3tica Da Vinci RAMIE menor invasivo<\/strong>. Conex\u00e3o com testicular<\/a>.<\/p>\n

BEP IGCCCG + EP + VeIP + TIP salvage + HDCT TI-CE auto-TMO + TIGER trial: o est\u00e1gio quimio<\/h2>\n

A terceira camada \u00e9 quimio sist\u00eamica. Padr\u00e3o setorial inclui (a) BEP bleomicina+etoposide+cisplatina 1L IGCCCG<\/strong> com bleomicina Blenoxane 30u D1+D8+D15 + etoposide Vepesid 100 mg\/m\u00b2 D1-5 + cisplatina Platinol 20 mg\/m\u00b2 D1-5 + ciclo 21d + good 3 BEP \/ intermediate 4 BEP \/ poor 4 BEP + cura 90+% good risk; (b) EP etoposide+cisplatina 4 cycles<\/strong> alternativa BEP + bleomicina toxicidade pulmonar contraindicada + ECOG 0-1 pacientes selecionados; (c) VeIP vinblastina+ifosfamida+cisplatina salvage 2L<\/strong> + TIP paclitaxel+ifosfamida+cisplatina salvage 2L PFS 24m HR favor\u00e1vel + GemOx gemcitabina+oxaliplatina 3L; (d) HDCT high-dose chemotherapy + auto-TMO aut\u00f3logo<\/strong> com TI-CE Mayo Clinic carbo+etoposide+ifosfamida + tandem 2 cycles + CMSP CD34+ \u22654-5\u00d710\u2076\/kg af\u00e9rese + Spectra Optia Terumo + condicionamento BEAM\/BU+CY\/melfalan + TIGER trial randomized HDCT vs conventional salvage; (e) outras<\/strong> late relapse 2y+ p\u00f3s-CR + brain metastasis monitoring RM+CT+TC + secondary malignancy AML+MDS p\u00f3s-etoposide+cisplatina+RT + cardiotoxicidade Adriamycin+bleomicina pulmonary fibrosis 5-10% + Raynaud + neuropathy + tinnitus + nephrotoxicity Lista C5.<\/p>\n

Cl\u00ednica com BEP+VeIP+TIP+HDCT TI-CE+TIGER madura escala BEP cura good risk 90+%<\/strong> + escala TIP salvage PFS 24m<\/strong> + escala HDCT TI-CE auto-TMO refractory 30-40% durable response<\/strong>. Conex\u00e3o com Lista C5<\/a>.<\/p>\n

Tr\u00eas perfis de PGRSS por capacidade testicular avan\u00e7ada<\/h2>\n

Cl\u00ednica testic avan s\u00f3 A1.<\/strong> 1 fluxo. Custo mensal R$ 9.000-26.000<\/strong> mas perda de A4+RPLND+E+sist\u00eamico.<\/p>\n

Cl\u00ednica testic avan A1 + A4 + BEP.<\/strong> 3 fluxos. Custo mensal R$ 22.000-54.000<\/strong>, captura cirurgia + sist\u00eamico padr\u00e3o.<\/p>\n

Cl\u00ednica testic avan 5 fluxos completos.<\/strong> A1+A4+C+E+sist\u00eamico + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 40.000-95.000<\/strong>, efic\u00e1cia 95%, ROI 800-2.500% via captura completa testicular avan\u00e7ada + BEP cura 90+% good + TIP salvage PFS 24m + HDCT TI-CE auto-TMO refractory.<\/p>\n

Os tr\u00eas erros que aparecem em cir oncol\u00f3gica testicular avan\u00e7ada<\/h2>\n

O primeiro \u00e9 a subdimensionamento BEP+VeIP+TIP+HDCT Lista C5<\/strong>. Sem segrega\u00e7\u00e3o bleomicina+etoposide+cisplatina+vinblastina+ifosfamida+paclitaxel+gemcitabina+oxaliplatina+carboplatina+ifosfamida+pembrolizumab+nivolumab + Lista C5 = n\u00e3o-conformidade ANVISA RDC 222 + risco contamina\u00e7\u00e3o cruzada profissional + impacto financeiro.<\/p>\n

O segundo \u00e9 a mistura A1 TGCT + IGCCCG good vs intermediate vs poor<\/strong>. Confunde rastreabilidade risk classification + impossibilita PRECOG+EORTC+GETUG protocolo padronizado + risco indica\u00e7\u00e3o inadequada (3 BEP good vs 4 BEP poor vs HDCT salvage refractory).<\/p>\n

O terceiro \u00e9 a falta de protocolo nerve-sparing + ejacula\u00e7\u00e3o anter\u00f3grada 80-95%<\/strong>. Sem t\u00e9cnica preservar plexo simp\u00e1tico lombar L1-L4 + bilateral preservation + RAMIE robotic-assisted + PC-RPLND template = perda fertility 5-20% template completo + zero qualidade vida + risco depress\u00e3o p\u00f3s-cir.<\/p>\n

A regula\u00e7\u00e3o de PGRSS testicular avan\u00e7ada no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com cir oncol\u00f3gica preservadora como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com PGRSS cl\u00ednicas especializadas<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A INCA C\u00e2ncer Test\u00edculo<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o PGRSS testicular avan\u00e7ada 5 fluxos oncol\u00f3gicos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a A1 TGCT seminoma puro 50%+n\u00e3o-seminoma 50% EC+YST+TER+CHC+CIS ITGCN GCNIS+marcador AFP alfa-fetoprote\u00edna+\u03b2-hCG+LDH seriado q3w+IGCCCG good+intermediate+poor risk+sobrevida 5y 90+\/80\/50-60%+PRECOG+EORTC GETUG+TE08+TE13+CID C62+TNM 8\u00aa, A4 orquiectomia radical inguinal alta+Chevassu maneuver+bi\u00f3psia contralateral CIS screening+RPLND modified template Donohue+full bilateral+nerve-sparing plexo simp\u00e1tico lombar L1-L4+ejacula\u00e7\u00e3o anter\u00f3grada 80-95%+PC-RPLND post-chemotherapy residual mass\u22651cm+necrose 40%+teratoma maduro 40%+yolk sac 20%+rob\u00f3tica Da Vinci Xi+SP+Medtronic Hugo+RAMIE+chyloperitoneum 5-15%+ileus 10-25%, C Iridium-192 brachy raro+I-131 met\u00e1stase raro+Y-90 SIRT raro+CNEN-NN-3.05, E bi\u00f3psia testicular contralateral 5% CIS+Vacutainer marcadores seriados, Lista C5 BEP bleomicina Blenoxane 30u+etoposide Vepesid 100 mg\/m\u00b2+cisplatina Platinol 20 mg\/m\u00b2+IGCCCG good 3 BEP cura 90+%+intermediate 4+poor 4+EP 4 cycles ECOG 0-1+VeIP vinblastina+ifosfamida+cisplatina salvage 2L+TIP paclitaxel+ifosfamida+cisplatina salvage 2L PFS 24m+GemOx 3L+HDCT high-dose chemo+auto-TMO aut\u00f3logo TI-CE Mayo Clinic carbo+etoposide+ifosfamida+tandem 2 cycles+CMSP CD34+af\u00e9rese Spectra Optia Terumo+TIGER trial randomized HDCT vs conventional salvage refractory 30-40% durable+late relapse+brain metastasis+secondary AML+MDS+cardiotoxicidade Adriamycin+bleomicina pulmonary fibrosis 5-10%+Raynaud+neuropathy+tinnitus+nephrotoxicity.<\/p>\n","protected":false},"excerpt":{"rendered":"

PGRSS testicular avan\u00e7ada: RPLND + BEP + HDCT + auto-TMO. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2314,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[2917,2712,3153,3152],"class_list":["post-2315","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-bep","tag-cirurgia-oncologica","tag-hdct","tag-testicular-avancada"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2315"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2315\/revisions"}],"predecessor-version":[{"id":4380,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2315\/revisions\/4380"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2314"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}